Patent: 6,869,952
✉ Email this page to a colleague
Summary for Patent: 6,869,952
| Title: | Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases |
| Abstract: | The present invention provides compounds of formula I, ##STR1## and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. |
| Inventor(s): | Bhide; Rajeev S. (Princeton Junction, NJ), Cai; Zhen-Wei (Belle Mead, NJ), Qian; Ligang (Hopewell, NJ), Barbosa; Stephanie (Lambertville, NJ) |
| Assignee: | Bristol Myers Squibb Company (Princeton, NJ) |
| Application Number: | 10/623,171 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,869,952
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Microbix Biosystems Inc. | KINLYTIC | urokinase | For Injection | 021846 | 01/16/1978 | ⤷ Try a Trial | 2022-07-19 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2022-07-19 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2022-07-19 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2022-07-19 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2022-07-19 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2022-07-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
